Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.KV Pharmaceutical Company has been cleared by the FDA to market a generic version of Purdue Pharma's pain drug MS Contin in 100mg and 200mg strengths.
Subscribe to our email newsletter
This approval now allows Ethex Corporation, KV’s wholly-owned generic/non-branded subsidiary, to offer a full line of all strengths of this product.
Ethex Corporation has commenced the launch of these two new strengths into its current line of 15mg, 30mg and 60mg morphine extended release tablets. The company believes these two strengths will be a positive addition and will allow Ethex to increase its market share position for its full product line offering.
KV said that while this is a highly genericized market, these two strengths have shown unit market growth year-over-year, according to IMS.